{
    "clinical_study": {
        "@rank": "10093", 
        "arm_group": {
            "arm_group_label": "PF-06650808", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To assess the safety and tolerability at increasing dose levels of PF-06650808 in patients\n      with advanced solid tumors in order to determine the maximum tolerated dose and select the\n      recommended Phase 2 dose."
        }, 
        "brief_title": "A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neoplasms", 
            "Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or\n             for which no standard therapy is available\n\n          -  Previously treated metastatic triple negative breast cancer that expresses Notch3\n             with at least one measurable lesion\n\n          -  Adequate bone marrow, renal and liver function\n\n        Exclusion Criteria:\n\n          -  Major surgery, radiation therapy or systemic anti-cancer therapy within 4 weeks of\n             starting study treatment\n\n          -  Patients with known symptomatic brain metastases requiring steroids\n\n          -  Prior treatment with a compound of the same mechanism"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "55", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02129205", 
            "org_study_id": "B7501001"
        }, 
        "intervention": [
            {
                "arm_group_label": "PF-06650808", 
                "description": "Dose Escalation Phase [Part 1] - PF-06650808 will be administered at doses starting at 0.2 mg/kg.  Increases in dose will continue until MTD is determined.", 
                "intervention_name": "PF-06650808", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PF-06650808", 
                "description": "Dose Expansion Phase [Part 2] - Patients will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.", 
                "intervention_name": "PF-06650808", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "solid tumors", 
            "triple negative breast cancer", 
            "PF-06650808", 
            "Phase 1"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7501001&StudyName=A%20Dose%20Escalation%20Study%20of%20PF-06650808%20in%20Patients%20with%20Advanced%20Solid%20Tumors%20"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Santa Monica", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90404"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43221"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43212"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of PF-06650808 In Patients With Advanced Solid Tumors", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "First cycle DLTs in order to determine maximum tolerated dose", 
                "measure": "Number of participants with Dose-Limiting Toxicities (DLT) [Part 1]", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 up to Day 21"
            }, 
            {
                "description": "Response rate as determined by RECIST v 1.1", 
                "measure": "Number of participants with objective response [Part 2]", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and every 6 weeks until disease progression, unacceptable toxicity, or up to 24 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02129205"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months"
            }, 
            {
                "measure": "Area Under the Curve from Time Zero to end of dosing interval (AUCtau)", 
                "safety_issue": "No", 
                "time_frame": "Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months"
            }, 
            {
                "description": "CL is a quantitative measure of the rate at which a drug substance is removed from the body.", 
                "measure": "Systemic Clearance (CL)", 
                "safety_issue": "No", 
                "time_frame": "Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months"
            }, 
            {
                "description": "Number of participants with the presence of anti-PF-06650808 antibodies", 
                "measure": "Incidence of anti-drug antibodies", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 15, 21, and every 21 days thereafter up to 24 months"
            }, 
            {
                "measure": "Number of participants with objective response, PFS and OS [Part 2]", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and every 6 weeks until disease progression, unacceptable toxicity, or up to 24 months"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.", 
                "measure": "Volume of Distribution at Steady State (Vss)", 
                "safety_issue": "No", 
                "time_frame": "Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}